{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T09:10:11Z","timestamp":1744017011671,"version":"3.40.3"},"reference-count":30,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2024,7,22]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>Our aim was to describe the visual outcomes and determine the clinical factors in ischaemic retinal vasculitis (IRV) that were predictive of a poor visual prognosis or infectious aetiology.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Retrospective cohort study of consecutive presentations of IRV to Auckland District Health Board from 2009 to 2022.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n    <jats:p>The median age at presentation was 39.2 years and 108 (53.7%) were women. The total median follow-up was 4.8 years. Infectious aetiology was present in 151 eyes (52.1%). Moderate visual loss (20\/50 to 20\/200) occurred in 20 eyes (6.9%) and severe visual loss (\u226420\/200) occurred in 41 eyes (14.1%). Median visual acuity was 20\/30 (IQR 20\/25 to 20\/100) on presentation and 20\/25 (IQR 20\/20 to 20\/50) at final follow-up. Retinitis (HR 4.675 p=0.048) and cystoid macular oedema (CME) (HR 7.265\u2009p&lt;0.001) were significantly associated with vision loss. There was concurrent macular ischaemia in 26 eyes (19.4%) and CME in 52 eyes (17.9%). Retinitis was predictive of infectious aetiology (p=0.006) and cotton wool spots for non-infectious aetiology (p&lt;0.001). Retinal haemorrhage (HR 5.580 p=0.001), retinal vein occlusion (HR 5.071 p=0.001) and quadrants of ischaemia (HR 2.222 p=0.025) were significantly associated with vitreous haemorrhage.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In patients with IRV, 21% of affected individuals sustained moderate-to-severe vision loss over 5 years. Ultra-widefield fluorescein angiography can be used to quantify the risk of neovascular complications and guide treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bjo-2024-325775","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T17:21:25Z","timestamp":1722532885000},"page":"209-214","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Visual outcomes and prognostic factors in ischaemic retinal vasculitis"],"prefix":"10.1136","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4912-0594","authenticated-orcid":false,"given":"Aaron","family":"Yap","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne L","family":"Sims","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4311-859X","authenticated-orcid":false,"given":"Rachael L","family":"Niederer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"2025040422453029000_109.2.209.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"2025040422453029000_109.2.209.2","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-200312000-00015"},{"key":"2025040422453029000_109.2.209.3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/eye.1996.71","article-title":"Visual outcome of patients with idiopathic ischaemic and non-ischaemic retinal vasculitis","volume":"10 (Pt 3)","author":"Palmer","year":"1996","journal-title":"Eye (Lond)"},{"key":"2025040422453029000_109.2.209.4","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/197675","article-title":"Ischemic retinal vasculitis and its management","volume":"2014","author":"Talat","year":"2014","journal-title":"J Ophthalmol"},{"key":"2025040422453029000_109.2.209.5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajo.2017.02.028","article-title":"Clinical outcome of retinal vasculitis and predictors for prognosis of ischemic retinal vasculitis","volume":"177","author":"Sharief","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"2025040422453029000_109.2.209.6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/09273940591003828","article-title":"Retinal vasculitis","volume":"13","author":"Abu El-Asrar","year":"2005","journal-title":"Ocul Immunol Inflamm"},{"key":"2025040422453029000_109.2.209.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-008-0926-0"},{"key":"2025040422453029000_109.2.209.8","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181e36c6d"},{"key":"2025040422453029000_109.2.209.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(13)38013-0"},{"key":"2025040422453029000_109.2.209.10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10792-009-9301-3","article-title":"A clinical approach to the diagnosis of retinal vasculitis","volume":"30","author":"El-Asrar","year":"2010","journal-title":"Int Ophthalmol"},{"key":"2025040422453029000_109.2.209.11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/eye.1993.81","article-title":"Macular ischaemia in posterior uveitis","volume":"7 (Pt 3)","author":"Bentley","year":"1993","journal-title":"Eye (Lond)"},{"key":"2025040422453029000_109.2.209.12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4103\/0301-4738.94059","article-title":"Fulminant toxoplasmic retinochoroiditis following intravitreal triamcinolone administration","volume":"60","author":"Rush","year":"2012","journal-title":"Indian J Ophthalmol"},{"key":"2025040422453029000_109.2.209.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.06.058"},{"key":"2025040422453029000_109.2.209.14","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1442-9071.2006.01229.x","article-title":"Acute retinal necrosis post intravitreal injection of triamcinolone acetonide","volume":"34","author":"Toh","year":"2006","journal-title":"Clinical Exper Ophthalmology"},{"key":"2025040422453029000_109.2.209.15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5935\/0004-2749.20150030","article-title":"Acute retinal necrosis following intravitreal dexamethasone (Ozurdex\u00ae) implant","volume":"78","author":"Kucukevcilioglu","year":"2015","journal-title":"Arq Bras Oftalmol"},{"key":"2025040422453029000_109.2.209.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-007-0549-x"},{"key":"2025040422453029000_109.2.209.17","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1080\/09273948.2020.1860230","article-title":"Infectious uveitis after local steroid and\/or methotrexate injections at a tertiary referral center in New Zealand: a case series","volume":"30","author":"Pc Ong","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"2025040422453029000_109.2.209.18","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200110000-00004"},{"key":"2025040422453029000_109.2.209.19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2990.2003.00499.x"},{"key":"2025040422453029000_109.2.209.20","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(85)90091-1"},{"key":"2025040422453029000_109.2.209.21","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-310210"},{"key":"2025040422453029000_109.2.209.22","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1097\/IAE.0000000000000218","article-title":"Spectral domain optical coherence tomography in the evaluation and management of infectious retinitis","volume":"34","author":"Kurup","year":"2014","journal-title":"Retina (Philadelphia, Pa)"},{"key":"2025040422453029000_109.2.209.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-013-2334-3"},{"key":"2025040422453029000_109.2.209.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.10.006"},{"key":"2025040422453029000_109.2.209.25","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(90)90004-Y"},{"key":"2025040422453029000_109.2.209.26","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-300774"},{"key":"2025040422453029000_109.2.209.27","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1976.03910030475008"},{"key":"2025040422453029000_109.2.209.28","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.76.8.499"},{"key":"2025040422453029000_109.2.209.29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0161-6420(84)34296-8","article-title":"Retinal periphlebitis and retinitis in multiple sclerosis. I. Pathologic characteristics","volume":"91","author":"Arnold","year":"1984","journal-title":"Ophthalmology"},{"key":"2025040422453029000_109.2.209.30","unstructured":"PHARMAC . Decision to fund aflibercept and rivaroxaban. Available: https:\/\/pharmac.govt.nz\/news-and-resources\/consultations-and-decisions\/decision-to-fund-aflibercept-and-rivaroxaban [Accessed 3 May 2018]."}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2024-325775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T08:41:20Z","timestamp":1744015280000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2024-325775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1,28]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bjo-2024-325775"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2024-325775","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"type":"print","value":"0007-1161"},{"type":"electronic","value":"1468-2079"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}